Skip to main content
Erschienen in: Indian Journal of Pediatrics 8/2019

17.01.2019 | Review Article

Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach

verfasst von: H. Simon Schaaf

Erschienen in: Indian Journal of Pediatrics | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Approximately 25,000 children develop multidrug-resistant (MDR) tuberculosis (TB) each year, but few of them are diagnosed and appropriately treated for MDR-TB. New diagnostic tools have improved our ability to diagnose children with bacteriologically confirmed TB earlier. However, the majority of childhood TB cases are not bacteriologically confirmed; therefore a high index of suspicion is needed, and taking a detailed history of contact with drug-resistant source cases and previous TB treatment is important to identify presumed MDR-TB cases. Treatment for MDR-TB is rapidly changing with the addition of new and repurposed drugs, the introduction of shorter regimens and the move towards injectable-free, all-oral MDR-TB treatment regimens. Children have been neglected in the introduction of the new drugs, but drug dosing and safety studies are now being completed. This article presents a practical approach in deciding which regimen to use in individual children in need of MDR-TB treatment. Outcomes in those treated are generally good, but only <5% of children with MDR-TB are currently diagnosed and appropriately treated. Diagnosing children with MDR-TB and getting them on to correct treatment regimens should now be our main focus.
Literatur
2.
Zurück zum Zitat Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16:1193–201.CrossRefPubMed Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16:1193–201.CrossRefPubMed
3.
Zurück zum Zitat Schaaf HS, Marais BJ, Hesseling AC, Brittle W, Donald PR. Surveillance of antituberculosis drug resistance amongst children from the Western Cape Province of South Africa – an upward trend. Am J Public Health. 2009;99:1486–90.CrossRefPubMedPubMedCentral Schaaf HS, Marais BJ, Hesseling AC, Brittle W, Donald PR. Surveillance of antituberculosis drug resistance amongst children from the Western Cape Province of South Africa – an upward trend. Am J Public Health. 2009;99:1486–90.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Schaaf HS, Gie RP, Beyers N, Sirgel FA, de Klerk PJ, Donald PR. Primary drug-resistant tuberculosis in children. Int J Tuberc Lung Dis. 2000;4:1149–55.PubMed Schaaf HS, Gie RP, Beyers N, Sirgel FA, de Klerk PJ, Donald PR. Primary drug-resistant tuberculosis in children. Int J Tuberc Lung Dis. 2000;4:1149–55.PubMed
5.
Zurück zum Zitat Seddon JA, Furin JJ, Gale M, Del Castillo Barrientos H, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med. 2012;186:953–64.CrossRefPubMed Seddon JA, Furin JJ, Gale M, Del Castillo Barrientos H, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med. 2012;186:953–64.CrossRefPubMed
6.
Zurück zum Zitat Parr JB, Mitnick CD, Atwood SS, Chalco K, Bayona J, Becerra MC. Concordance of resistance profiles in households of patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2014;58:392–5.CrossRefPubMed Parr JB, Mitnick CD, Atwood SS, Chalco K, Bayona J, Becerra MC. Concordance of resistance profiles in households of patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2014;58:392–5.CrossRefPubMed
7.
Zurück zum Zitat Shah NS, Yuen CM, Heo M, Tolman AW, Becerra MC. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2014;58:381–91.CrossRefPubMed Shah NS, Yuen CM, Heo M, Tolman AW, Becerra MC. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2014;58:381–91.CrossRefPubMed
8.
Zurück zum Zitat Schaaf HS, Van Rie A, Gie RP, et al. Transmission of multidrug resistant tuberculosis. Pediatr Infect Dis J. 2000;19:695–9.CrossRefPubMed Schaaf HS, Van Rie A, Gie RP, et al. Transmission of multidrug resistant tuberculosis. Pediatr Infect Dis J. 2000;19:695–9.CrossRefPubMed
9.
Zurück zum Zitat Seddon JA. Time to be a bit more ‘surgical’ in our management of children with drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19:625.CrossRefPubMed Seddon JA. Time to be a bit more ‘surgical’ in our management of children with drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19:625.CrossRefPubMed
10.
Zurück zum Zitat Schaaf HS, Garcia-Prats AJ, McKenna L, Seddon JA. Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. Expert Rev Clin Pharmacol. 2018;11:233–44.CrossRefPubMed Schaaf HS, Garcia-Prats AJ, McKenna L, Seddon JA. Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. Expert Rev Clin Pharmacol. 2018;11:233–44.CrossRefPubMed
11.
Zurück zum Zitat Raizada N, Sachdeva KS, Nair SA, et al. Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB. PLoS One. 2014;9:e105346.CrossRefPubMedPubMedCentral Raizada N, Sachdeva KS, Nair SA, et al. Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB. PLoS One. 2014;9:e105346.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Schaaf HS, Garcia-Prats AJ. Multidrug-resistant tuberculosis in children: recent developments in diagnosis, treatment and prevention. Curr Pediatr Rep. 2016;4:53–62.CrossRef Schaaf HS, Garcia-Prats AJ. Multidrug-resistant tuberculosis in children: recent developments in diagnosis, treatment and prevention. Curr Pediatr Rep. 2016;4:53–62.CrossRef
13.
Zurück zum Zitat Tagliani E, Cabibbe AM, Miotto P, et al. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. J Clin Microbiol. 2015;53:2961–9.CrossRefPubMedPubMedCentral Tagliani E, Cabibbe AM, Miotto P, et al. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. J Clin Microbiol. 2015;53:2961–9.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Allix- Béguec C, Arandjelovic I, Bi L, et al. CRyPTIC Consortium and the 100,000 Genomes Project. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N Engl J Med. 2018;379:1403–15.CrossRefPubMed Allix- Béguec C, Arandjelovic I, Bi L, et al. CRyPTIC Consortium and the 100,000 Genomes Project. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N Engl J Med. 2018;379:1403–15.CrossRefPubMed
15.
Zurück zum Zitat Outhred AC, Jelfs P, Suliman B, et al. Added value of whole genome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother. 2015;70:1198–202.PubMed Outhred AC, Jelfs P, Suliman B, et al. Added value of whole genome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother. 2015;70:1198–202.PubMed
16.
Zurück zum Zitat Du Preez K, Schaaf HS, Dunbar R, et al. Complementary surveillance strategies are needed to better characterise the epidemiology, are pathways and treatment outcomes of tuberculosis in children. BMC Public Health. 2018;18:397.CrossRefPubMedPubMedCentral Du Preez K, Schaaf HS, Dunbar R, et al. Complementary surveillance strategies are needed to better characterise the epidemiology, are pathways and treatment outcomes of tuberculosis in children. BMC Public Health. 2018;18:397.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Wiseman CA, Gie RP, Starke JR, et al. A proposed comprehensive classification of tuberculosis disease severity in children. Pediatr Infect Dis J. 2012;31:347–52.CrossRefPubMed Wiseman CA, Gie RP, Starke JR, et al. A proposed comprehensive classification of tuberculosis disease severity in children. Pediatr Infect Dis J. 2012;31:347–52.CrossRefPubMed
18.
Zurück zum Zitat Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax. 2014;69:458–64.CrossRefPubMed Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax. 2014;69:458–64.CrossRefPubMed
19.
21.
Zurück zum Zitat Seddon JA, Schaaf HS, Marais BJ, et al. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. Lancet Respir Med. 2018;6:662–4.CrossRefPubMed Seddon JA, Schaaf HS, Marais BJ, et al. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. Lancet Respir Med. 2018;6:662–4.CrossRefPubMed
23.
Zurück zum Zitat Weyer K, Falzon D, Jaramillo E. Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis. Bull World Health Organ. 2018;96:667–667A.CrossRefPubMedPubMedCentral Weyer K, Falzon D, Jaramillo E. Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis. Bull World Health Organ. 2018;96:667–667A.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Schaaf HS, Thee S, van der Laan L, Hesseling AC, Garcia-Prats AJ. Adverse effects of second-line antituberculosis drugs in children. Expert Opin Drug Saf. 2016;15:1369–81.CrossRefPubMed Schaaf HS, Thee S, van der Laan L, Hesseling AC, Garcia-Prats AJ. Adverse effects of second-line antituberculosis drugs in children. Expert Opin Drug Saf. 2016;15:1369–81.CrossRefPubMed
25.
Zurück zum Zitat Garcia-Prats AJ, Rose PC, Draper HR, et al. Effect of co-administration of lidocaine on the pain and pharmacokinetics of intramuscular amikacin in children with multidrug-resistant tuberculosis: a randomized crossover trial. Pediatr Infect Dis J. Published ahead of print, 14 Mar 2018. https://doi.org/10.1097/INF.0000000000001983 PMID: 29561515. Garcia-Prats AJ, Rose PC, Draper HR, et al. Effect of co-administration of lidocaine on the pain and pharmacokinetics of intramuscular amikacin in children with multidrug-resistant tuberculosis: a randomized crossover trial. Pediatr Infect Dis J. Published ahead of print, 14 Mar 2018. https://​doi.​org/​10.​1097/​INF.​0000000000001983​ PMID: 29561515.
27.
Zurück zum Zitat Selvakumar N, Kumar V, Balaji S, et al. High rates of ofloxacin resistance in Mycobacterium tuberculosis among both new and previously treated patients in Tamil Nadu. South India. PLoS One. 2015;10:e0117421.CrossRefPubMedPubMedCentral Selvakumar N, Kumar V, Balaji S, et al. High rates of ofloxacin resistance in Mycobacterium tuberculosis among both new and previously treated patients in Tamil Nadu. South India. PLoS One. 2015;10:e0117421.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Seddon JA, Thee S, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in children treated for multidrug-resistant tuberculosis. J Inf Secur. 2013;66:320–9. Seddon JA, Thee S, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in children treated for multidrug-resistant tuberculosis. J Inf Secur. 2013;66:320–9.
30.
Zurück zum Zitat Zhao Y, Fox T, Manning K, et al. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: a retrospective cohort study. Clin Infect Dis. 2018 Aug 24. https://doi.org/10.1093/cid/ciy727. Zhao Y, Fox T, Manning K, et al. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: a retrospective cohort study. Clin Infect Dis. 2018 Aug 24. https://​doi.​org/​10.​1093/​cid/​ciy727.​
31.
Zurück zum Zitat Brill MJ, Svensson EM, Pandie M, et al. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. Int J Antimicrob Agents. 2017;49:212–7.CrossRefPubMed Brill MJ, Svensson EM, Pandie M, et al. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. Int J Antimicrob Agents. 2017;49:212–7.CrossRefPubMed
32.
Zurück zum Zitat Mallikaarjun S, Wells C, Petersen C, et al. Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects. Antimicrob Agents Chemother. 2016;60:5976–85.CrossRefPubMedPubMedCentral Mallikaarjun S, Wells C, Petersen C, et al. Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects. Antimicrob Agents Chemother. 2016;60:5976–85.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J. 2012;40:1277–86.CrossRefPubMed Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J. 2012;40:1277–86.CrossRefPubMed
34.
Zurück zum Zitat Osman M, Harausz EP, Garcia-Prats AJ, et al. For the collaborative Group for Meta-Analysis of Paediatric individual patient data in MDR-TB. Encouraging treatment outcomes among children with extensively drug-resistant tuberculosis: a global systematic review and individual patient meta-analysis. Emerg Infect Dis. 2018; in press. Osman M, Harausz EP, Garcia-Prats AJ, et al. For the collaborative Group for Meta-Analysis of Paediatric individual patient data in MDR-TB. Encouraging treatment outcomes among children with extensively drug-resistant tuberculosis: a global systematic review and individual patient meta-analysis. Emerg Infect Dis. 2018; in press.
35.
Zurück zum Zitat Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:449–56.CrossRefPubMed Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:449–56.CrossRefPubMed
36.
Zurück zum Zitat Harausz EP, Garcia-Prats AJ, Law S, et al. Collaborative Group for Meta-Analysis of Paediatric individual patient data in MDR-TB. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med. 2018;15:e1002591.CrossRefPubMedPubMedCentral Harausz EP, Garcia-Prats AJ, Law S, et al. Collaborative Group for Meta-Analysis of Paediatric individual patient data in MDR-TB. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med. 2018;15:e1002591.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5:e898–906.CrossRefPubMedPubMedCentral Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5:e898–906.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Svensson EM, du Bois J, Kitshoff R, et al. Relative bioavailability of bedaquiline tablets suspended in water: implications for dosing in children. Br J Clin Pharmacol. 2018;84:2384–92.CrossRefPubMedCentral Svensson EM, du Bois J, Kitshoff R, et al. Relative bioavailability of bedaquiline tablets suspended in water: implications for dosing in children. Br J Clin Pharmacol. 2018;84:2384–92.CrossRefPubMedCentral
Metadaten
Titel
Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach
verfasst von
H. Simon Schaaf
Publikationsdatum
17.01.2019
Verlag
Springer India
Erschienen in
Indian Journal of Pediatrics / Ausgabe 8/2019
Print ISSN: 0019-5456
Elektronische ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-018-02846-8

Weitere Artikel der Ausgabe 8/2019

Indian Journal of Pediatrics 8/2019 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.